MADISON, Wis., July 16 /PRNewswire-FirstCall/ -- Third Wave
Technologies Inc. (Nasdaq: TWTI) today announced that it has signed a
pharmacogenetics collaboration agreement with Laboratory Corporation of
America(R) Holdings (LabCorp(R)) (NYSE: LH), one of the world's largest
reference laboratories and a pioneer in commercializing new diagnostic
technologies, to develop a companion diagnostic to help physicians
personalize treatment for heart failure patients.
